Medications For Weight Loss
42 articles on Medications For Weight Loss, written by Shotlee and medically reviewed for clinical accuracy.
Ozempic, Wegovy, and Mounjaro May Alter Taste: How Food Flavor Changes Can Impact Cravings
Discover how incretin-based therapies like Ozempic, Wegovy, and Mounjaro might be changing the way you experience food. This article delves into new research linking altered taste perception to reduced appetite and cravings, offering insights for patients and clinicians.
8 min read
Ozempic & Wegovy Online: The Risky Rush to Bypass Doctor Consultations
The surge in GLP-1 medications for weight loss has led to a concerning trend: many online pharmacies are prescribing these powerful drugs with minimal to no doctor consultation, putting patients at significant risk.
6 min read
Medicare's $50 GLP-1 Weight Loss Drug Trial: Who Qualifies?
For many older Americans, the high cost of GLP-1 weight loss medications has been a significant barrier. Now, a new Medicare trial offers a lifeline, potentially making these life-changing drugs accessible for just $50 a month. This article breaks down what you need to know about the Medicare GLP-1 Bridge program, including who qualifies, which medications are covered, and the program's future.
8 min read
Medicare's GLP-1 Weight Loss Drug Bridge: What You Need to Know
For the first time, Medicare is expanding access to GLP-1 medications for weight loss through a new pilot program. Starting July 1, eligible beneficiaries can access popular drugs like Wegovy and Zepbound for a $50 monthly copay. This groundbreaking initiative aims to make these life-changing treatments more accessible, but understanding the specifics is crucial.
7 min read
Wegovy & Mounjaro: Navigating Medicare's New Path to Weight Loss
For years, Medicare's stance on GLP-1 medications for weight loss was a firm 'no.' However, a significant shift is underway. Discover how the new 'Bridge' program opens doors to crucial weight management tools like Wegovy and Mounjaro, and what you need to know.
6 min read
Ozempic, Wegovy, Mounjaro: Navigating the New GLP-1 Landscape
The landscape of GLP-1 medications for weight loss and chronic disease management is rapidly evolving. From new access programs to shifting pricing dynamics, understanding these advancements is crucial for patients and healthcare providers alike.
6 min read
Ozempic, Wegovy & Mounjaro: Navigating the GLP-1 Weight Loss Revolution
The global surge in GLP-1 medications for weight loss has sparked a vital conversation in India. While innovators like Nithin Kamath highlight affordability and potential, industry leaders like Kiran Mazumdar-Shaw urge careful consideration. This article delves into the nuances of these transformative drugs, their benefits, the hurdles to long-term adoption, and what they mean for your health journey.
7 min read
GLP-1s & Telehealth: Navigating Risks and Ensuring Safety
The booming popularity of GLP-1 medications for weight loss has coincided with a dramatic rise in telehealth services. This article delves into the benefits and significant risks of obtaining these powerful drugs online, highlighting critical safety concerns and offering guidance for patients.
6 min read
Serena Williams Champions GLP-1s: Ads Air Amidst Tennis Comeback
Tennis legend Serena Williams is making waves both on and off the court. As she returns to professional tennis, advertisements featuring her advocacy for GLP-1 medications are set to air, highlighting a significant cultural moment for weight management therapies.
6 min read
GLP-1 Drugs & Your Knees: New Research on Joint Health
Discover how GLP-1 medications, known for weight loss, may also significantly reduce the need for knee replacement surgery. This article delves into the latest research and its implications for joint health.
7 min read
Ozempic, Wegovy, Mounjaro: Will Weight Loss Drug Costs Skyrocket for You?
The soaring popularity and effectiveness of GLP-1 medications for weight loss are undeniably reshaping healthcare landscapes. But as demand surges, so do the costs, leading to significant implications for both employers and the individuals who rely on these treatments. This article delves into the financial pressures, employer strategies, and what you can expect regarding your co-pays and coverage for drugs like Ozempic, Wegovy, and Mounjaro.
8 min read
GLP-1 Weight Loss Drugs: Rising Costs & What It Means for Your Wallet
The soaring popularity and effectiveness of GLP-1 medications for weight loss are driving up healthcare costs, leading to potential increases in employee co-pays and changes in employer coverage strategies. This article explores the financial implications and what you need to know.
6 min read
Driving on Ozempic & Mounjaro: Avoiding the £1,000 DVLA Fine
New regulations warn that GLP-1 medication users could face significant fines if side effects impair driving. Here is the complete guide to staying safe and compliant.
8 min read
Understanding Peptides: Beyond the Hype of GLP-1s and Skincare
Peptides are powerful signaling molecules, but they are not a universal cure-all. This deep dive clarifies the function of GLP-1 agonists, cosmetic peptides, and the critical importance of medical guidance when considering peptide therapies for weight management or anti-aging.
6 min read
GLP-1 Weight Loss Drugs: Usage Trends and What You Need to Know
The popularity of GLP-1 receptor agonists for weight management is soaring. This article delves into the latest trends, the science behind these medications, and essential considerations for patients and healthcare providers.
7 min read
Military's $700M GLP-1 Spending: Weight Loss Solutions or Taxpayer Burden?
The U.S. military has spent nearly $726 million on GLP-1 medications since 2021. This article delves into the controversy surrounding this expenditure, examining the obesity crisis within the armed forces and the debate over these weight-loss drugs.
7 min read
Medicaid GLP-1 Coverage Changes: Access to Ozempic and Wegovy
A growing number of state Medicaid programs are restricting or eliminating coverage for GLP-1 medications like Ozempic and Wegovy for obesity treatment due to budget constraints.
8 min read
GLP-1 Weight Loss Drugs: The Risk of Stopping and Restarting
New research suggests that the effectiveness of popular GLP-1 weight loss medications may significantly diminish with intermittent use. Understand the implications for your health journey.
7 min read
GLP-1s and Hair Loss: Understanding the Link & Treatment Options
The rise of GLP-1 medications for weight loss has brought to light a common side effect: temporary hair thinning. This article delves into why this happens and what you can do about it.
8 min read
GLP-1 Drugs: New Hope for Depression and Motivation?
A recent study published in JAMA Psychiatry has unveiled promising findings regarding GLP-1 receptor agonists, such as semaglutide, and their potential to address a core symptom of major depressive disorder: a lack of motivation. This article delves into the study's methodology, results, and the broader implications for mental health treatment.
8 min read
Duodenal Resurfacing: A New Hope Beyond GLP-1 Weight Loss?
The emergence of GLP-1 receptor agonists has revolutionized obesity treatment, but concerns about weight regain upon discontinuation are significant. New research on duodenal mucosal resurfacing suggests a potential breakthrough in maintaining weight loss long-term.
7 min read
Duodenal Resurfacing May Prevent Weight Regain After Stopping Ozempic
New research presented at Digestive Disease Week 2026 suggests a minimally invasive 'gut reset' procedure could help patients maintain weight loss after discontinuing GLP-1 medications like Ozempic and Wegovy. The findings address a major challenge in obesity treatment: weight regain after stopping therapy.
7 min read
News Personalities' Before & After Ozempic, GLP-1 Weight Loss Pics
Ozempic and other GLP-1 medications are transforming figures in Hollywood and newsrooms alike, with before and after pics of personalities like Oprah Winfrey and Joy Behar showcasing undeniable weight loss. A 2024 study highlights their history since 1986, exploding in popularity post-Wegovy's 2021 FDA approval for weight loss. Spot the telltale Ozempic neck and hands that give away users.
5 min read
Luke Combs Rejects GLP-1 for Weight Loss: 'Not the Short Way'
Country music sensation Luke Combs is turning down GLP-1 medications for weight loss, opting for the hard road instead. In a candid New York Times interview, he shares fears about his appearance affecting his career and why 'that stuff scares me more than the benefits.' This stance highlights debates around quick fixes versus lifelong habits in weight management.
4 min read
Heather Gay's Ozempic Weight Loss Journey: RHOSLC Star's Transformation
Real Housewives of Salt Lake City star Heather Gay has shared her Ozempic-assisted weight loss journey, crediting the GLP-1 injection for noticeable results after initial slow progress. Losing around 30 pounds amid social pressures from friends' transformations, she called it a 'long, overdue glow-up' thanks to modern medicine. Despite Ozempic face rumors, Gay remains open about her experience.
4 min read
Oprah Winfrey 'Ozempic Feet' Rumors Hard to Ignore
Oprah Winfrey's dramatic weight loss at Paris Fashion Week in March 2026 fueled 'Ozempic feet' rumors, with videos capturing her slow, shuffling steps. Social media users speculated GLP-1 drugs weakened her muscles and aged her prematurely. Earlier gossip from the NAACP Image Awards highlighted similar concerns about veiny, sagging foot skin.
5 min read
Hims & Hers Stock: Costly Wegovy Deal Challenges
Hims & Hers has resolved its dispute with Novo Nordisk, shifting to official weight loss drugs like Wegovy over controversial compounded GLP-1 alternatives. This brings legal clarity but slams profitability with higher costs and a cautious Q1 2026 revenue outlook of $600-625 million. With 2.5 million subscribers, can the stock rebound amid debt and investigations?
4 min read
Expanding Access to GLP-1 Weight-Loss Meds is Essential
Obesity rates hit 40% in 2022, but GLP-1 drugs are turning the tide with 15-20% weight loss. USC Schaeffer Center research shows broad access could add nearly two years of life for young adults and save Medicare $175-245 billion. Yet, limited insurance coverage blocks millions from these life-changing treatments.
5 min read
Luke Combs on Skipping GLP-1s for Weight Loss: 'Not the Short Way'
Grammy-nominated country singer Luke Combs revealed on The New York Times' Popcast why GLP-1 weight loss drugs aren't for him: he wants to 'beat myself' the hard way. Motivated by his wife and kids, Combs embraces the struggle over quick fixes amid lifelong weight battles. His story highlights the personal choice in pursuing metabolic health.
6 min read
Experts on Hims & Hers' $1.15B Eucalyptus Acquisition
Hims & Hers is acquiring Australian telehealth firm Eucalyptus for $1.15 billion to fuel global growth amid U.S. regulatory scrutiny over compounded GLP-1s. Experts call it a smart diversification move that complements weight loss and wellness services. This expansion could reshape access to personalized care worldwide.
5 min read
Hims & Hers GLP-1 Pill Launch Backfires, Fuels Compounder Crackdown
Hims & Hers aimed to disrupt the GLP-1 market with a cheap oral semaglutide pill, but faced swift FDA backlash and a patent lawsuit from Novo Nordisk. The retreat highlights regulatory risks for compounders as branded supplies stabilize. This analysis reveals challenges in oral GLP-1 production and future paths for telehealth weight loss offerings.
6 min read
Joy Behar Reveals GLP-1 Weight Loss: 'I Was Prediabetic' on The View
On The View, Joy Behar opened up about her GLP-1 weight loss success, noting she was prediabetic before starting. Co-host Sunny Hostin shared gaining 40 lbs during COVID and using Mounjaro to improve her cholesterol from 200 to 140. These stories highlight Hollywood's trend toward Ozempic and similar drugs for real health gains.
5 min read
Farida Jalal Jabs Sajid Nadiadwala's 27-Inch Waist Amid Ozempic Rumors
Bollywood veteran Farida Jalal couldn't resist a cheeky remark about producer Sajid Nadiadwala's impressive 27-inch waistline, fueling ongoing rumors that Ozempic fueled his dramatic body transformation. As his film O Romeo hits theaters, the chatter highlights growing celebrity interest in GLP-1 medications for weight loss. Explore the story and science behind it.
5 min read
Eli Lilly Shares Face Pressure Amid GLP-1 Market Shifts
Eli Lilly posted blockbuster Q4 2025 results with $19.29B revenue, yet shares near $1,020 face selling pressure from compounded semaglutide competition and government pricing initiatives. Hims & Hers' $49 pill undercuts Zepbound's $299 intro dose, signaling shifts in the GLP-1 market. Investors eye Orforglipron's FDA decision amid pipeline cuts.
5 min read
5 Things to Know Before Switching to Oral GLP-1 Pills
Oral GLP-1 medications offer a convenient alternative to weekly injections for weight loss. Discover the main differences in absorption, dosing, and routine. Follow these 5 tips to ensure a successful switch without losing progress.
2 min read
Wegovy Pill in New Jersey Stores: Where to Obtain It
The new Wegovy GLP-1 pill for weight loss is now accessible in New Jersey stores. With growing interest in these medications, this guide covers availability, pricing, and key safety information. Health tracking apps like Shotlee can assist in monitoring progress during use.
2 min read
Monster of 2025: GLP-1 Promotions
The year 2025 has seen a relentless barrage of ads promoting GLP-1 medications for weight loss, often bypassing FDA approvals and focusing on cosmetic benefits. Despite regulations limiting their use to specific medical conditions, telehealth companies push compounded versions aggressively. This trend threatens to undermine the body positivity movement by exploiting insecurities for profit.
5 min read
Tablets, TikTok, and Weight-Loss Applications: The Consumer-Centric Upcoming Era of GLP-1 Medications
The landscape of GLP-1 medications for weight loss is shifting towards consumer-driven models, with pill versions offering flexibility and telehealth platforms making access easier. Industry experts envision daily routines incorporating these drugs alongside apps, while concerns arise about medical oversight and long-term effects. This evolution could expand the market significantly, driven by affordability and marketing.
6 min read
GLP-1 Medications & Weight Loss: Jonathan Van Ness's Journey & Your Health
Jonathan Van Ness recently shared his experience with GLP-1 medications for weight loss. This post delves into the science behind these medications, their impact on metabolic health, and how to make informed choices about your well-being.
4 min read
Zepbound at Walmart: Expanding Access to GLP-1 Medications for Weight Loss
Eli Lilly's Zepbound is now available at Walmart pharmacies, making it easier for individuals to access this GLP-1 medication. This expansion offers a convenient option for those seeking weight loss support and managing their metabolic health.
3 min read
GLP-1s & Weight Loss: Separating Fact from Fiction in Reality TV
The use of GLP-1 medications for weight loss is a hot topic, even among reality TV stars. We break down the debate, explore healthier alternatives, and discuss the importance of holistic health tracking.
3 min read
Peptide Therapy & Alcohol: How GLP-1 Agonists Like Semaglutide May Reduce Cravings
New research suggests that GLP-1 agonists, like semaglutide, may reduce alcohol cravings and delay intoxication. The effect is linked to slowed gastric emptying, impacting alcohol absorption. Track your peptide journey and wellness goals using Shotlee.